Liquidia Corporation (NASDAQ:LQDA) Receives Average Rating of “Moderate Buy” from Analysts

Liquidia Corporation (NASDAQ:LQDA) has been assigned an average recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, two have given a hold recommendation, five have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $98.0833.

Several research firms have commented on LQDA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research report on Friday, July 17th. Wells Fargo & Company increased their price target on shares of Liquidia from $62.00 to $108.00 and gave the stock an “overweight” rating in a report on Thursday. Bank of America lifted their price objective on Liquidia from $79.00 to $92.00 and gave the company a “neutral” rating in a report on Thursday. Royal Bank Of Canada set a $130.00 target price on Liquidia in a research note on Friday, July 24th. Finally, HC Wainwright set a $36.00 price target on shares of Liquidia in a report on Friday, July 24th.

Liquidia Trading Down 8.5%

LQDA opened at $72.10 on Friday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. Liquidia has a one year low of $21.15 and a one year high of $93.61. The business’s 50-day simple moving average is $78.42 and its 200-day simple moving average is $55.00. The company has a market cap of $6.41 billion, a P/E ratio of 52.63 and a beta of 0.58.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 237.10% and a net margin of 30.74%.The company had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. During the same quarter in the prior year, the firm posted ($0.49) EPS. The firm’s quarterly revenue was up 1842.1% compared to the same quarter last year. As a group, equities research analysts expect that Liquidia will post 3.02 EPS for the current fiscal year.

Insider Buying and Selling at Liquidia

In related news, Director Paul B. Manning sold 200,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $63.91, for a total value of $12,782,000.00. Following the sale, the director directly owned 716,311 shares in the company, valued at $45,779,436.01. The trade was a 21.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Stephen M. Bloch sold 242,269 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $70.43, for a total transaction of $17,063,005.67. Following the completion of the sale, the director directly owned 1,176,184 shares in the company, valued at $82,838,639.12. This trade represents a 17.08% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,756,861 shares of company stock valued at $122,981,112 in the last ninety days. Corporate insiders own 25.60% of the company’s stock.

Hedge Funds Weigh In On Liquidia

Several institutional investors and hedge funds have recently modified their holdings of LQDA. GSA Capital Partners LLP increased its stake in Liquidia by 63.6% in the fourth quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock valued at $2,179,000 after purchasing an additional 24,555 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Liquidia by 63.3% in the 1st quarter. The Manufacturers Life Insurance Company now owns 58,265 shares of the company’s stock valued at $2,199,000 after purchasing an additional 22,592 shares during the last quarter. State of New Jersey Common Pension Fund D acquired a new position in Liquidia in the fourth quarter valued at $709,000. WCG Wealth Advisors LLC lifted its stake in shares of Liquidia by 98.2% in the 4th quarter. WCG Wealth Advisors LLC now owns 54,411 shares of the company’s stock valued at $1,877,000 after purchasing an additional 26,957 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Liquidia by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company’s stock worth $138,439,000 after buying an additional 52,671 shares during the period. Hedge funds and other institutional investors own 64.54% of the company’s stock.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA sales drove substantial growth. Second-quarter net product sales reached approximately $170.4 million, up 31% from the first quarter. Liquidia reported about 5,900 prescriptions and more than 5,000 patients treated since the product’s June 2025 launch. Liquidia Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Revenue and profitability improved sharply. Total revenue was $171.7 million, up more than 1,800% year over year and ahead of the $168.5 million consensus estimate. Net income reached $74.7 million, adjusted EBITDA was $96.3 million, and cash increased to $284.2 million. LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth
• Positive Sentiment: Management maintains an ambitious growth outlook. Liquidia is targeting more than $1 billion in net revenue in 2027 as YUTREPIA gains market share. The company is also advancing 10 clinical studies involving YUTREPIA and L606, potentially expanding its inhaled-treprostinil pipeline. LQDA Q2 Earnings Call Highlights YUTREPIA and $1B 2027 Revenue Path
• Positive Sentiment: Several analysts raised their targets. Needham increased its target to $110 from $70 and BTIG raised its target to $111 from $109, both maintaining buy ratings. Bank of America lifted its target to $92 from $79 but retained a neutral rating.
• Neutral Sentiment: Results were mixed relative to expectations. Diluted earnings per share were $0.74, slightly below the $0.76 consensus estimate, despite the revenue beat. The miss may have disappointed investors after a major run-up in the stock and contributed to profit-taking. Liquidia shares fall after second-quarter earnings miss despite revenue growth
• Negative Sentiment: Future spending and valuation remain risks. Research and development expenses increased substantially as Liquidia prepares for the Phase 3 L606 program. In addition, reported insider activity shows extensive selling over the past six months, which may weigh on sentiment.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).